6673-35-4 Usage
Chemical Properties
N-[4-[2-HYDROXY-3-[(1-METHYLETHYL)AMINO]PROPOXY]PHENYL]ACETAMIDE is White Solid
Originator
Eraldin, I.C.I. ,UK,1970
Uses
Different sources of media describe the Uses of 6673-35-4 differently. You can refer to the following data:
1. Practolol is a selective adrenergic β-receptor blocking drug with antihyperstensive activity. Practolol has been used in the emergency treatment of cardiac arrhythmias.
2. N-[4-[2-HYDROXY-3-[(1-METHYLETHYL)AMINO]PROPOXY]PHENYL]ACETAMIDE is a selective adrenergic β-receptor blocking drug with antihyperstensive activity. N-[4-[2-HYDROXY-3-[(1-METHYLETHYL)AMINO]PROPOXY]PHENYL]ACETAMIDE has been used in the emergency treatment of cardiac arrhythmias.
Definition
ChEBI: N-(4-Hydroxyphenyl)acetamide in which the hydrogen of the phenolic hydroxy group is substituted by a 3-(isopropylaminoamino)-2-hydroxypropyl group. A selective beta blocker, it has been used in the emergency treatment of cardiac arrhythm
as.
Manufacturing Process
The 1-(4-acetamidophenoxy)-2,3-epoxypropane used as starting material may be obtained as follows. To a solution of 4.5 parts of 4-acetamidophenol and 1.5 parts of sodium hydroxide in 50 parts of water at 15°C, there is added 3.5 parts of epichlorohydrin. The mixture is stirred for 16 hours at ambient temperature, filtered and the solid residue is washed with water. There is thus obtained 1-(4-acetamidophenoxy)-2,3-epoxypropane, MP 110°C.A mixture of 2 parts of 1-(4-acetamidophenoxy)-2,3-epoxypropane and 10 parts of isopropylamine is stirred at ambient temperature for 16 hours. The resulting solution is evaporated to dryness under reduced pressure and the residue is crystallized from butyl acetate. There is thus obtained 1-(4acetamidophenoxy)-3-isopropylamino-2-propanol, MP 134° to 136°C.
Brand name
A 25;Cardiol;Cordialina;Eraldina;Pralon;Teranol.
Therapeutic Function
Antiarrhythmic
World Health Organization (WHO)
Practolol, a beta-adrenoreceptor antagonist, was introduced in
1970 for the treatment of angina and cardiac dysrhythmias. By 1974 long-term use
had been associated with serious delayed idiosyncratic reactions (oculomucocutaneous
syndrome) and this led to the withdrawal of oral preparations by
the major manufacturer on a worldwide basis. There is no evidence to suggest that
other beta-adrenoreceptor antagonist are associated with this risk. Intravenous
preparations of practolol remain available in many countries for the emergency
treatment of selected cardiac dysrhythmias.
Biological Activity
Practolol is a potent and selective β1 adrenergic receptor antagonist. It can be used in the study of cardiac arrhythmias.
in vitro
Practolol (10 μM; 30 min) preferentially antagonizes the relaxant effects produced by R0363 in spontaneously contracted tracheal preparations from the guinea-pig.Practolol (10 nM-100 μM) blocks the progesterone production induced by (-)epinephrine in a dose-dependent manner in granulosa cells.
in vivo
Practolol (0.5 mg/kg; i.v.) decreases heart rate, left ventricular dP/dt max , myocardial blood flow and cardiac output in intact close-chest dogs.Practolol (0.5 mg/kg; i.v.) decreases normal myocardial blood flow but flow in the ischaemic area remains unchanged after coronary artery ligation.
Check Digit Verification of cas no
The CAS Registry Mumber 6673-35-4 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 6,6,7 and 3 respectively; the second part has 2 digits, 3 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 6673-35:
(6*6)+(5*6)+(4*7)+(3*3)+(2*3)+(1*5)=114
114 % 10 = 4
So 6673-35-4 is a valid CAS Registry Number.
InChI:InChI=1/C14H22N2O3/c1-10(2)15-8-13(18)9-19-14-6-4-12(5-7-14)16-11(3)17/h4-7,10,13,15,18H,8-9H2,1-3H3,(H,16,17)/p+1/t13-/m0/s1
6673-35-4Relevant articles and documents
Redox-Neutral Selenium-Catalysed Isomerisation of para-Hydroxamic Acids into para-Aminophenols
Chuang, Hsiang-Yu,Schupp, Manuel,Meyrelles, Ricardo,Maryasin, Boris,Maulide, Nuno
, p. 13778 - 13782 (2021/03/31)
A selenium-catalysed para-hydroxylation of N-aryl-hydroxamic acids is reported. Mechanistically, the reaction comprises an N?O bond cleavage and consecutive selenium-induced [2,3]-rearrangement to deliver para-hydroxyaniline derivatives. The mechanism is studied through both 18O-crossover experiments as well as quantum chemical calculations. This redox-neutral transformation provides an unconventional synthetic approach to para-aminophenols.
THERAPY FOR COMPLICATIONS OF DIABETES
-
, (2009/07/02)
A method for enhancing glycemic control and/or insulin sensitivity in a human subject having diabetic nephropathy and/or metabolic syndrome comprises administering to the subject a selective endothelin A (ETA) receptor antagonist in a glycemic control and/or insulin sensitivity enhancing effective amount. A method for treating a complex of comorbidities in an elderly diabetic human subject comprises administering to the subject a selective ETA receptor antagonist in combination or as adjunctive therapy with at least one additional agent that is (i) other than a selective ETA receptor antagonist and (ii) effective in treatment of diabetes and/or at least one of said comorbidities other than hypertension. A therapeutic combination useful in such a method comprises a selective ETA receptor antagonist and at least one antidiabetic, anti-obesity or antidyslipidemic agent other than a selective ETA receptor antagonist.
Method for treating resistant hypertension
-
, (2008/06/13)
A method is provided for lowering blood pressure in a patient having clinically diagnosed resistant hypertension. The method comprises administering darusentan to the patient adjunctively with a baseline antihypertensive regimen that comprises administration of at least one diuretic and at least two antihypertensive drugs selected from at least two of (a) ACE inhibitors and angiotensin II receptor blockers, (b) beta-adrenergic receptor blockers and (c) calcium channel blockers. The darusentan is orally administered at a dose and frequency effective, in combination with the baseline regimen, to provide a reduction of at least about 3 mmHg in one or more blood pressure parameters selected from trough sitting systolic, trough sitting diastolic, 24-hour ambulatory systolic, 24-hour ambulatory diastolic, maximum diurnal systolic and maximum diurnal diastolic blood pressures.
